NFKB1 and neoplasm: In a mouse model with subcutaneous Pan02, NRTUA monotherapy reduced tumor growth by invading intratumoral DC, activating MyD88/NF-κB signaling, and generating high levels of IL-12 that chemoattracted and primed de novo infiltrates of cytotoxic CD8+ T cells.